跳至主要内容
临床试验/NCT00545844
NCT00545844已完成4 期

An 8 Week Study to Evaluate the Effectiveness of Adding Montelukast to Inhaled Corticosteroid (ICS) to the ICS/Long-Acting Beta 2-Agonist Therapy in Adult Subjects With Asthma and Allergic Rhinitis

Organon and Co0 个研究点目标入组 313 人开始时间: 2007年4月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
313
主要终点
Asthma Control

研究概览

简要总结

Effectiveness of adding montelukast to inhaled corticosteroids in adult subjects with both uncontrolled asthma and allergic rhinitis.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
15 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient is a user of Inhaled Corticosteroid (ICS) or ICS/Long-Acting Beta 2-Agonist (ICS/LABA) at any dosage
  • Peak expiratory flow is > or = 80% of predicted value on the day of visit 1
  • Uncontrolled as per Canadian asthma consensus guidelines

排除标准

  • Unwilling to stop regular use of histamine H1 antagonists for allergic rhinitis symptoms
  • Unwilling to stop use of antihistamine eye drops or cromoglycate eye drops or ophthalmic corticosteroid

研究组 & 干预措施

1

Experimental

montelukast sodium

干预措施: montelukast sodium (Drug)

结局指标

主要结局

Asthma Control

时间窗: 8 weeks (from Week 0 to Week 8)

Asthma control was assessed by the Canadian Asthma Consensus Guidelines at week 0 and week 8. Patients were considered uncontrolled if they answered "yes" to at least 2 of the 8 asthma control parameters.

次要结局

  • The Mean Change in Mini Rhinoconjunctivitis Quality of Life Questionnaire (MiniRQLQ) Overall Score(8 weeks (from Week 0 to Week 8))
  • Effectiveness of Montelukast Therapy Used in Combination With Inhaled Corticosteroids or Inhaled Corticosteroids / Long-Acting Beta 2-Agonist in Improving the Symptoms of Asthma Using the Asthma Control Questionnaire (ACQ)(8 weeks (from Week 0 to Week 8))

研究者

申办方类型
Industry
责任方
Sponsor

相似试验